Multi-omic machine learning predictor of breast cancer therapy response
Source check: Needs source check. Not independent scientific confirmation.
Finding: ML integration of clinical, pathology, genomic and transcriptomic features from 168 pre-treatment biopsies predicted pathology response to chemotherapy with or without HER2-targeted therapy.
Technology: Multi-omic machine-learning predictor
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Predictive model integrated multi-omic features.
- Test and result
- Retrospective cohort; external validation not assessed from the abstract.
- Limitation / still unknown
- Not a clinical-benefit test.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/search?query=DOI:10.1038/s41586-021-04278-5
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 17 Nov 2026. Review scope: Europe PMC metadata and abstract only; Methods not read..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.